

Melatonin - Oral

Source: [https://webprod.hc-sc.gc.ca/nhp/ids/bdipsn/atReq?atid=melatonin.oral\(=eng](https://webprod.hc-sc.gc.ca/nhp/ids/bdipsn/atReq?atid=melatonin.oral(=eng)

Extracted: 2025-08-26T06:34:49.502384

MELATONIN - Oral Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section. (PDF Version - 97 KB) This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. Notes Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion. The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant. Rules for the application of this monograph when combined with other monographs: Products containing melatonin must not indicate any uses or purposes related to the maintenance/support of good/general health. Products providing a quantity of melatonin that meets the minimum therapeutic dose must indicate a use or purpose associated with melatonin. Date April 26, 2024 Proper name(s), Common name(s), Source information Table 1. Proper name(s), Common name(s), Source information Proper name(s) Common name(s) Source information Source ingredient(s) Preparation(s) N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide N-Acetyl-5-methoxytryptamine Melatonin Pineal hormone Melatonin Synthetic References: Proper names: RSC 2023; Buscemi et al. 2004; Common names: RSC 2023; Buscemi et al. 2004; Source information: RSC 2023. Route of Administration Oral Dosage Form(s) This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document. Acceptable dosage forms for oral use are indicated in the dosage form drop-down list of the web-based Product Licence Application form for Compendial applications. Note that this list does not include prolonged-release, extended-release or delayed-release dosage forms. Use(s) or Purpose(s) (Used as a) sleep aid (to help promote sleep) (Costello et al. 2014; Wyatt et al. 2006; Brzezinski et al. 2005). Helps increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule (e.g. shift-work and jet lag) (Zhdanova et al. 2001; Brusco et al. 1999; Sanders et al. 1999; Skene et al. 1999; Garfinkel et al. 1995; Sack et al. 1991). Helps (to) prevent and/or reduce the effects of jet lag/minimize jet lag (e.g. daytime fatigue, sleep disturbance) (for people/if travelling by plane easterly across two or more time zones/flying east over two or more time zones) (Brown et al. 2009; Herxheimer and Petrie 2002; Suhner et al. 1998a; Petrie et al. 1993; Claustrat et al. 1992; Petrie et al. 1989). Helps (to) speed up/reduce the time it takes to fall asleep (sleep onset latency aspect of sleep quality) in people who fall asleep slowly/with delayed sleep phase disorder (van Geijlswijk et al. 2010). Helps (to) re-set the body's sleep-wake cycle (aspect of the circadian rhythm) (van Geijlswijk et al. 2010; Kunz et al. 2004; Sack et al. 2000). Note The above claims can be combined on the product label (e.g. Helps re-set the body's sleep-wake cycle (aspect of the circadian rhythm) and increase the total sleep time (aspect of sleep quality) in people suffering from sleep restriction or altered sleep schedule). Dose(s) Subpopulation(s) Adults 18 years and older Quantity(ies) All uses except jet lag 0.1-10 milligrams of melatonin, per day (Brzezinski et al. 2005; IOM 2004; Kayumov et al. 2001; Koda-Kimble 2001; Zhdanova et al. 2001; Brusco et al. 1999; Jean-Louis et al. 1999; Matsumoto 1999; Sack et al. 1997; Attenburrow et al. 1996; Garfinkel 1995; Zhdanova et al. 1995; Tzischinsky and Lavie 1994; Dollins et al. 1994; Dahlitz et al. 1991; James et al. 1987). Jet lag 0.5-10 milligrams of melatonin, per day (Brown et al. 2009; Herxheimer and Petrie 2002; Suhner et al. 1998a). Direction(s) for use Take as needed, 30 to 60 minutes before bedtime (Andersen et al. 2016; Zhdanova et al. 2001, 1995; Nave et al. 1995). Duration(s) of Use No statement required. Risk Information Caution(s) and warning(s) All uses Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993). Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993). When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002;

Holliman and Chyka 1997). When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b). Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002). Contraindication(s) Do not use if you are pregnant or breastfeeding (IOM 2004). Known adverse reaction(s) Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002). Non-medicinal ingredients Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database. Storage conditions Must be established in accordance with the requirements described in the Natural Health Products Regulations. Specifications The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide. The medicinal ingredient must comply with the requirements outlined in the NHPID. EXAMPLE OF PRODUCT FACTS: Consult the Guidance Document, Labelling of Natural Health Products for more details. References Cited Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, Gögenur I. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. *BMC Pharmacology and Toxicology*. 2016 Dec;17(1):1-5. Arangino S, Cagnacci A, Angiolucci M, Vacca AMB, Longu G, Volpe A, Melis GB. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. *American Journal of Cardiology* 1999; 83(9):1417-1419. Attenburrow ME, Cowen PJ, Sharpley AL. Low dose melatonin improves sleep in healthy middle-aged subjects. *Psychopharmacology (Berlin)* 1996;126(2):179-181. Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. *Annals of Medicine* 1998;30(1):122-130. Brown GM, Pandi-Perumal SR, Trakht I, Cardinali DP. Melatonin and its relevance to jet lag. *Travel Medicine and Infectious Disease* 2009;7:69-81. Brusco LI, Fainstein I, Marquez M, Cardinali DP. Effect of melatonin in selected populations of sleep-disturbed patients. *Biological Signals and Receptors* 1999;8(1-2):126-131. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on sleep: a meta-analysis. *Sleep Medicine Reviews* 2005;9:41-50. Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T 2004. Melatonin for treatment of sleep disorders. Evidence Report/Technology Assessment No. 108. AHRQ Publication No. 05-E002-2. Rockville (MD): U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. November, 2004. Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P, Volpe A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. *Clinical Endocrinology (Oxford)* 2001a;54(3):339-346. Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. *Journal of Pineal Research* 2002;32(4):277-278. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. *Endocrine* 2005;27:189-200. Claustrat B, Brun J, David M, Sassolas G, Chazot G. Melatonin and jet lag: confirmatory result using a simplified protocol. *Biological Psychiatry* 1992;32(8):705-711. Costello RB, Lentino CV, Boyd CC, O'Connell ML, Crawford CC, Sprengel ML, Deuster PA. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. *Nutrition journal* 2014;13:1-7. Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. *Lancet* 1991;337(8750):1121-1124. der Marderosian A, Beutler JA, editors. 2003. *The Review of Natural Health Products*, 3rd edition. St. Louis (MO): Facts and Comparisons®, a Wolters Kluwer Company. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. *Pharmacotherapy: A Pathophysiological Approach*. 5th edition. New York (NY): McGraw-Hill Co. Inc.; 2002. Dollins AB, Lynch HJ, Wurtman RJ, Deng MH, Lieberman HR. Effects of illumination on human nocturnal serum melatonin levels and performance. *Physiology and Behavior* 1994;53(1):153-160. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. *Lancet* 1995;346(8974):541-544. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. *European journal of clinical pharmacology*. 2015 Aug;71:901-9. Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. *British Journal of Clinical Pharmacology* 2003;56(6):679-682. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. *Cochrane Database of Systematic Reviews* 2002 Issue 2. Art. No.: CD001520. DOI: 10.1002/14651858.CD001520. [Accessed 2023 August 22]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958662/pdf/CD001520.pdf> IOM 2004: Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements. Prototype monograph on melatonin. Dietary Supplement Ingredient Prototype Monographs, Developed as Examples for the Report Dietary Supplements: A Framework for Evaluating Safety. Institute of Medicine and the National Research Council of the National Academies, Washington (DC): National Academies Press 2004: D1-D71. James SP, Mendelson WB, Sack DA, Rosenthal NE, Wehr TA. The effect of melatonin on normal sleep. *Neuropsychopharmacology* 1987;1(1):41-44. Jean-Louis G, von Gizycki H, Zizi F. Predictors of subjective sleepiness induced by melatonin administration. *Journal of Psychosomatic Research* 1999;47(4):355-358. Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind,

placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. *Psychosomatic Medicine* 2001;63(1):40-48. Koda-Kimble MA, editor. *Applied Therapeutics: The Clinical Use of Drugs*. Baltimore (MD): Lippincott Williams and Wilkins; 2001. Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. *Journal of Clinical Endocrinology & Metabolism* 2004;89(1):128-134. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. *British Journal of Clinical Pharmacology* 2000;49:423-427. Maestroni GJM. The immunoneuroendocrine role of melatonin. *Journal of Pineal Research* 1993;14(1):1-10. Matsumoto M. The hypnotic effects of melatonin treatment on diurnal sleep in humans. *Psychiatry and Clinical Neurosciences* 1999;53(2):243-245. Murray MT, Pizzorno Jr JE, Bongiorno PB. Melatonin. In: Pizzorno Jr JE, Murray MT. *Textbook of Natural Medicine*. Third edition. Chapter 105, pages 1057-1064. St.Louis (MI): Churchill Livingstone Elsevier; 2006. Naguib M, Samarkandi AH. Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. *British Journal of Anaesthesia* 1999;82(6):875-80. Nave R, Peled R, Lavie P. Melatonin improves evening napping. *European journal of pharmacology*. 1995 Mar 6;275(2):213-6. Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. *Best practice & research. Clinical endocrinology & metabolism* 2010;24(5):829-841. Petrie K, Dawson AG, Thompson L, Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. *Biological Psychiatry* 1993;33(7): 526-530. Petrie K, Conaglen JV, Thompson L, Chamberlain K. Effect of melatonin on jet lag after long haul flights. *British Medical Journal* 1989;298(6675):705-707. RSC 2023: Royal Society of Chemistry: The Merck Index Online [Accessed 2023 August 14]. Available from: <https://merckindex.rsc.org/> Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. *New England Journal of Medicine* 2000;343 (15):1070-1077. Sack RL, Lewy AJ, Blood ML, Stevenson J, Keith LD. Melatonin administration to blind people: phase advances and entrainment. *Journal of Biological Rhythms* 1991;6(3):249-261. Sanders DC, Chaturvedi AK, Hordinsky JR. Melatonin: aeromedical, toxicopharmacological, and analytical aspects. *Journal of Analytical Toxicology* 1999;23(3):159-167. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. *Lancet* 1998;351:1254. Skene DJ, Lockley SW, Arendt J. Melatonin in circadian sleep disorders in the blind. *Biological Signals and Receptors* 1999;8(1-2):90-95. Suhner A, Schlagenhauf P, Johnson R, Tschopp A, Steffen R. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. *Chronobiology International* 1998a;15(6):655-656. Suhner A, Schlagenhauf P, Tschopp A, Hauri-Bionda R, Friedrich-Koch A, Steffen R. Impact of melatonin on driving performance. *Journal of Travel Medicine* 1998b;5(1):7-13. Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. *American Journal of respiratory and critical care medicine* 2002;166:1055-1061. Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. *Journal of Allergy and Clinical Immunology* 2003;112(3):513-517. Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. *Sleep* 1994;17(7):638-645. van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. *Sleep* 2010;33(12):1605-1614. Wyatt JK, Dijk DJ, Cecco AR, Ronda JM, Czeisler CA. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. *Sleep* 2006;29(5):609-618. Wirtz PH, Spillmann M, Bärtschi C, Ehlert U, von Känel R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. *Journal of Pineal Research* 2008;44:127-133. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, Matheson JK, Schomer DL 1995. Sleep-inducing effects of low doses of melatonin ingested in the evening. *Clinical Pharmacology & Therapeutics* 57(5):552-558. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. *Journal of Clinical Endocrinology and Metabolism* 2001;86(10):4727-4730. Zisapel N. Melatonin and sleep. *The Open Neuroendocrinology Journal*. 2010 Sep 23;3(1). References Reviewed Abbas A, Raju J, Milles J, Ramachandran S. A circadian rhythm sleep disorder: melatonin resets the biological clock. *The Journal of the Royal College of Physicians of Edinburgh* 2010;40(4):311-313. Aicardi J. Epilepsy in brain-injured children. Review article. *Developmental Medicine and Child Neurology* 1990;32:191-202. Aksu F. Nature and prognosis of seizures in patients with cerebral palsy. *Developmental Medicine and Child Neurology* 1990;32:661-668. Andrade C, Srihari BS, Reddy KP, Chandramma L. Melatonin in medically ill patients with insomnia: a double blind placebo-controlled study. *Journal of Clinical Psychiatry* 2001;62(1):4145. Arendt J. Does melatonin improve sleep? *BMJ* 2006;332:550. Ashwal S, Russman BS, Blasco PA, Miller G, Dansler A, Shevell M, Stevenson R. Practice parameter: diagnostic assessment of the child with cerebral palsy. *Neurology* 2004;62:851-863. Bartoli AN, De Gregori S, Molinaro M, Broglio M, Tinelli C, Imberti R. Bioavailability of a new oral spray melatonin emulsion compared with a standard oral formulation in healthy volunteers. *Journal of Bioequivalence and Bioavailability* 2012;4(7):96-9. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. *Current Topics in Medicinal Chemistry* 2002;2(2):113-132. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on

sleep: a meta-analysis. *Sleep Medicine Reviews* 2005;9:41-50. Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. *Journal of Physiology* 2008;586:639-647. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. *British Medical Journal*, doi:10.1136/bmj.38731.532766.F6 (published 10 February 2006). Cagnacci A, Arangino S, Angiolucci M, Melis GB, Facchinetti F, Malmusi S, Volpe A. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. *Clinical Endocrinology* 2001b;54:261-266. Cagnacci A, Elliott JA, Yen SSC. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. *Journal of Clinical Endocrinology and Metabolism* 1992;75(2):447-452. Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. *American Journal of Psychiatry* 1976;133(10):1181-1186. Citera G, Arias MA, Maldonado, Cocco JA, Lazaro MA, Rosemffet MG, Brusco LI, Scheines EJ, Cardinali DP. The effect of melatonin in patients with fibromyalgia: a pilot study. *Clinical Rheumatology* 2000;19(1):9-13. Cutolo M, Villaggio B, Candido F, Valenti S, Giusti M, Felli L, Sulli A, Accardo S. Melatonin influences interleukin-12 and nitric oxide production by primary cultures of rheumatoid synovial macrophages and THP-1 cells. *Annals of the New York Academy of Sciences* 1999;876:246-254. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS. The absolute bioavailability of oral melatonin. *Journal of Clinical Pharmacology* 2000;40(7):781-784. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. *American Journal of Psychiatry* 1998;155(8):1119-1121. Ellis CM, Lemmens G, Parkes D. Melatonin and insomnia. *Journal of Sleep Research* 1996;5:61-65. Fauteck J-D, Schmidt H, Lerchl A, Kurlermann G, Wittkowski W. Melatonin in epilepsy: first results of replacement therapy and first clinical results. *Biological Signals and Receptors* 1999;8:105-110. GAO 2001: United States General Accounting Office. Report to Chairman, Special Committee on Aging, U.S. Senate. Health Products for Seniors: "Anti-Aging" Products Pose Potential for Physical and Economic Harm. September 2001. GAO-01-1129. [Accessed 2023 August 22] Available from: <https://www.gao.gov/assets/gao-01-1129.pdf> Goncalves AL, Martini Ferreira A, Teixeira Ribeiro R, Zukerman E, Cipolla-Neto J, Prieto Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. *Journal of Neurology, Neurosurgery & Psychiatry* 2016;87(10):1127-1132. Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, Kamari Y, Shen-Orr Z, Zisapel N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. *The American Journal of Medicine* 2006;119:898-902. Hadjipanayis A, Hadjichristodoulou C, Youroukos S. Epilepsy in patients with cerebral palsy. *Developmental Medicine and Child Neurology* 1997;39:659-663. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. *Sleep* 1995;18(7):598-603. Holliman BJ, Chyka PA. Problems in assessment of acute melatonin overdose. *Southern Medical Journal* 1997;90(4):451-453. Lewy AJ, Ahmed Saeeduddin, Latham Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. *Chronobiology International* 1992;9(5):380-392. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. *British Journal of Clinical Pharmacology* 2000;49:423-427. Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. *European Journal of Cancer* 1999;35(12):1688-1692. Munday K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. *Sleep* 2005;28(10):1271-1278. Neri B, De Leonardis V, Gemelli MT, Di Loro F, Mottola A. Ponchiatti R, Raugei A, Cini G. Melatonin as biological response modifier in cancer patients. *Anticancer Research* 1998;18:1329-1332. Ninomiya T, Iwatani N, Tomoda A, Miike T. Effects of exogenous melatonin on pituitary hormones in humans. *Clinical Physiology* 2001;21(3):292-299. Pandi-Perumal SR, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe AD, Kayumov L. Dim light melatonin onset (DLMO): A tool for the analysis of circadian phase in human sleep and chronobiological disorders. Review article. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2007;31:1-11. Pires MLN, Benedito-Silva AA, Pinto L, Souza L, Vismari L, Calil HM. Acute effects of low doses of melatonin on the sleep of young healthy subjects. *Journal of Pineal Research* 2001;31:326-332. Pizzorno Jr JEP, Murray MT. *Textbook of Natural Medicine*. 3rd edition, Volume 1. St-Louis (MI): Churchill Livingstone Elsevier; 2006. Reid KJ, Zee PC. Circadian rhythm sleep disorders. *Handbook of Clinical Neurology* 2011;99:963-977. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. *Annals of the New York Academy of Sciences* 2006;917:376-386. Scheer FAJL, Van Montfrans GA, van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. *Hypertension* 2004;43:192-197. Sletten TL, Vincenzi S, Redman JR, Lockley SW, Rajaratnam SMW. Timing of sleep and its relationship with the endogenous melatonin rhythm. *Frontiers in neurology* 2010;1:137. Suhner A, Schlagenhauf P, Johnson R, Tschopp A, Steffen R. Comparative study to determine the optimal melatonin

dosage form for the alleviation of jet lag. *Chronobiology International* 1998;15(6):655-656. Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status. *European Journal of Cancer* 1999;35:1688-1692. Vijayalaxmi CRT Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. *Journal of Clinical Oncology* 2002;20:2575-2601. Voordouw BCG, Euser R, Verdonk RER, Alberda BT, De Jong FH, Drogendijk AC, Fauser BCJM, Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. *Journal of Clinical Endocrinology and Metabolism* 1992;74(1):108-117. Zawilska JB, Nowak JZ. Melatonin: from biochemistry to therapeutic applications. *Polish Journal of Pharmacology* 1999;51:3-23. Zee PC. Shedding light on the effectiveness of melatonin for circadian rhythm sleep disorders. *Sleep* 2010;33(12):1581-1582 Zee PC. Shedding light on the effectiveness of melatonin for circadian rhythm sleep disorders. Commentary on van Geijlswijk et al. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. *Sleep* 2010;33:1605-1614. Zee PC, Goldstein CA. Treatment of shift work disorder and jet lag. *Current Treatment Options in Neurology* 2010;12(5):396-411. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. *Sleep*. 1996 Jul 1;19(5):423-31. Zhdanova IV and RJ Wurtman 1997. Efficacy of melatonin as a sleep-promoting agent. *Journal of Biological Rhythms* 12(6):644-650. Report a problem on this page Date modified: 2019-03-01

MEDICINAL INGREDIENT(S)

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

DOSAGE FORM(S)

Acceptable dosage forms for oral use are indicated in the dosage form drop-down list of the web-based Product Licence Application form for Compendial applications. Note that this list does not include prolonged-release, extended-release or delayed-release dosage forms.

USE(S) OR PURPOSE(S)

Products providing a quantity of melatonin that meets the minimum therapeutic dose must indicate a use or purpose associated with melatonin.

DOSE(S)

Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. *Journal of Clinical Endocrinology and Metabolism* 2001;86(10):4727-4730. Zisapel N. Melatonin and sleep. *The Open Neuroendocrinology Journal*. 2010 Sep 23;3(1).

RISK INFORMATION

Caution(s) and warning(s) All uses Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications for seizure, blood pressure, to suppress

the immune system, to affect mental state or increase sedation, steroids or blood thinners (Wirtz et al. 2008; IOM 2004; Herxheimer and Petrie 2002; Lusardi et al. 2000; Maestroni 1993). Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have cardiovascular, immune, liver or kidney disease, seizure disorder, asthma or diabetes (Peschke and Mühlbauer 2010; Carrillo-Vico et al. 2005; IOM 2004; der Marderosian and Beuttlers 2003; Sutherland et al. 2003; Calvo et al. 2002; Herxheimer and Petrie 2002; Sutherland et al. 2002; Cagnacci et al. 2001a; Arangino et al. 1999; Sheldon 1998; Maestroni 1993). When using this product avoid taking with alcohol or products that cause drowsiness (Herxheimer and Petrie 2002; Holliman and Chyka 1997). When using this product avoid driving or using machinery for 5 hours (Avery et al. 1998; Suhner et al. 1998b). Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Buscemi et al. 2004; IOM 2004; Dipiro et al. 2002). Contraindication(s) Do not use if you are pregnant or breastfeeding (IOM 2004). Known adverse reaction(s) Stop use if allergy occurs or if you experience headache, confusion, or nausea (Herxheimer and Petrie 2002).

NON-MEDICINAL INGREDIENTS

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

STORAGE CONDITION(S)

Must be established in accordance with the requirements described in the Natural Health Products Regulations.

SPECIFICATIONS

The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide. The medicinal ingredient must comply with the requirements outlined in the NHPID.

Proper name(s)	Common name(s)	Source information	
Source ingredient(s)	Preparation(s)		
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide N-Acetyl-5-methoxytryptamine	Melatonin	Melatonin	Synthetic